Overview
Zhengbo Song practices in Fushan, China. Song is rated as an Advanced expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, and EGFR Positive Lung Cancer.
Their clinical research consists of co-authoring 177 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Squamous Cell Lung Carcinoma.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Lung CancerSong isDistinguished. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Thymic Epithelial TumorSong isDistinguished. Learn about Thymic Epithelial Tumor.
- Advanced
- EGFR Positive Lung Cancer
- Lung AdenocarcinomaSong isAdvanced. Learn about Lung Adenocarcinoma.
- Pleural EffusionSong isAdvanced. Learn about Pleural Effusion.
- Squamous Cell Lung Carcinoma
- Experienced
- Acute PainSong isExperienced. Learn about Acute Pain.
- Adult Soft Tissue SarcomaSong isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Breast CancerSong isExperienced. Learn about Breast Cancer.
- Cardiac TamponadeSong isExperienced. Learn about Cardiac Tamponade.
- DiarrheaSong isExperienced. Learn about Diarrhea.
- Esophageal CancerSong isExperienced. Learn about Esophageal Cancer.